Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells

Toxicology in Vitro

Volumn 27, Issue 2, 2013, Pages 694-699

  Bae, Song Yi ^a   Kim, Gi Dae ^a   Jeon, Ju eun ^a   Shin, Jongheon ^a   Lee, Sang Kook ^a  

^a Seoul National University   (South Korea)

Author keywords

(19Z) Halichondramide; A549 human lung cancer cells; AMPK; G2 M cell cycle; GADD45; MTOR

Indexed keywords

ADENYLATE KINASE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HALICHONDRAMIDE; HALISHIGAMIDE D; INITIATION FACTOR 4E BINDING PROTEIN 1; JASPISAMIDE A; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEOHALICHONDRAMIDE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; S6 KINASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CHONDROSIN CORTICATA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ISOLATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPONGE (PORIFERA); UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MACROLIDES; MITOGEN-ACTIVATED PROTEIN KINASES; OXAZOLES; PORIFERA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

CHONDROSIA CORTICATA;

EID: 84871605340     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.11.001     Document Type: Article

References (29)

1. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M., Testa J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
2. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
3. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., O'Connell M., Shepherd F.A., Johnson B.E. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 2001, 19:1734-1742.
4. Chung H.J., Park E.J., Pyee Y., Hua Xu G., Lee S.H., Kim Y.S., Lee S.K. 25-Methoxyhispidol A, a novel triterpenoid of Poncirus trifoliata, inhibits cell growth via the modulation of EGFR/c-Src signaling pathway in MDA-MB-231 human breast cancer cells. Food Chem. Toxicol. 2011, 49:2942-2946.
5. Chung S.C., Lee S.H., Jang K.H., Park W., Jeon J.E., Oh H., Shin J., Oh K.B. Actin depolymerizing effect of trisoxazole-containing macrolides. Bioorg. Med. Chem. Lett. 2011, 21:3198-3201.
6. DiPaola R.S. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A.K. Tyagi et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. Cancer Res. 2002, 8:3512-3519. 2002, Clin. Cancer Res. 8, 3311-3314.
7. Faulkner D.J. Marine natural products. Nat. Prod. Rep. 2002, 19:1-48.
8. Fay J.R., Steele V., Crowell J.A. Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev. Res. (Phila) 2009, 2:301-309.
9. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 2005, 280:32081-32089.
10. Harvey A.L. Natural products in drug discovery. Drug Discov. Today 2008, 13:894-901.
11. Himes R.H., Kersey R.N., Heller-Bettinger I., Samson F.E. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976, 36:3798-3802.
12. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
13. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999, 39:295-312.
14. Kim E.H., Min H.Y., Chung H.J., Song J., Park H.J., Kim S., Lee S.K. Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Food Chem. Toxicol. 2012, 50:1060-1065.
15. Marinov M., Fischer B., Arcaro A. Targeting mTOR signaling in lung cancer. Crit. Rev. Oncol. Hematol. 2007, 63:172-182.
16. Matsunaga S., Nogata Y., Fusetani N. Thiomycalolides: new cytotoxic trisoxazole-containing macrolides isolated from a marine sponge Mycale sp. J. Nat. Prod. 1998, 61:663-666.
17. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2:533-543.
18. Raez L.E., Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer. Curr. Opin. Oncol. 2006, 18:156-161.
19. Rakovitch E., Mellado W., Hall E.J., Pandita T.K., Sawant S., Geard C.R. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44:1119-1124.
20. Shin J., Lee H.S., Kim J.Y., Shin H.J., Ahn J.W., Paul V.J. New macrolides from the sponge Chondrosia corticata. J. Nat. Prod. 2004, 67:1889-1892.
21. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
22. Sirirak T., Kittiwisut S., Janma C., Yuenyongsawad S., Suwanborirux K., Plubrukarn A. Kabiramides J and K, trisoxazole macrolides from the sponge Pachastrissa nux. J. Nat. Prod. 2011, 74:1288-1292.
23. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
24. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
25. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
26. Wang X.W., Zhan Q., Coursen J.D., Khan M.A., Kontny H.U., Yu L., Hollander M.C., O'Connor P.M., Fornace A.J., Harris C.C. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. USA 1999, 96:3706-3711.
27. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
28. Yun H., Ha J. AMP-activated protein kinase modulators: a patent review (2006-2010). Expert Opin. Ther. Pat. 2011, 21:983-1005.
29. Zhang X.W., Jiang J.F., Xu B. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol. Sin. 2000, 21:364-368.